A composition for the controlled release of a nucleic acid such as short interfering RNA or messenger RNA,comprising silicon nanoparticles, at least one amino acid,and at least one lipid, wherein the silicon nanoparticles comprise at least 50% by weight silicon. Also related compositions and methods.

A composition for the controlled release of a nucleic acid such as short interfering RNA or messenger RNA,comprising silicon nanoparticles, at least one amino acid,and at least one lipid, wherein the silicon nanoparticles comprise at least 50% by weight silicon. Also related compositions and methods.

The present invention relates to a sterile buffered eye topical composition containing metabolites of the fermentation of Lactobacillus pertaining to the species casei or paracasei and for ophthalmic use of the composition in the prevention or treatment of microbial eye infections, eye allergies, vernal keratoconjunctivitis and keratoconjunctivitis sicca and blepharitis.

The present invention relates to a sterile buffered eye topical composition containing metabolites of the fermentation of Lactobacillus pertaining to the species casei or paracasei and for ophthalmic use of the composition in the prevention or treatment of microbial eye infections, eye allergies, vernal keratoconjunctivitis and keratoconjunctivitis sicca and blepharitis.

This disclosure features compositions comprising niclosamide for use in treating one or more conditions (or one or more symptoms thereof) characterized by an abnormal inflammatory response in one or more particular subject (e.g., patient) populations in need thereof. Such conditions include, e.g., an autoimmune disorder, e.g., colitis, e.g., autoimmune colitis, e.g, an inflammatory bowel disease, e.g., Crohn's disease, ulcerative colitis. In some embodiments, the uses include rectally (e.g., via enema) administering niclosamide.

Isolated peptides capable of reducing the amount of dexamethasone-induced spleen and/or thymus weight loss in a mouse are disclosed. Uses thereof for treating inflammatory or degenerative diseases are also disclosed.

The present disclosure provides compositions and methods of restoring or enhancing visual function in an individual by administering to the individual a pharmaceutical composition comprising a recombinant adeno-associated viral (rAAV) vector having a polynucleotide sequence that encodes a medium wavelength cone opsin (MW-opsin). The MW-opsin is expressed in a retinal cell in the individual, thereby restoring or enhancing visual function.

The present disclosure provides compositions and methods of restoring or enhancing visual function in an individual by administering to the individual a pharmaceutical composition comprising a recombinant adeno-associated viral (rAAV) vector having a polynucleotide sequence that encodes a medium wavelength cone opsin (MW-opsin). The MW-opsin is expressed in a retinal cell in the individual, thereby restoring or enhancing visual function.

Isolated polypeptides having enhanced affinity for a PDGF receptor and/or a VEGF receptor are provided. Compositions comprising the polypeptides and methods of use thereof are also provided.

Isolated polypeptides having enhanced affinity for a PDGF receptor and/or a VEGF receptor are provided. Compositions comprising the polypeptides and methods of use thereof are also provided.